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Abstract: 
Spasticity is a frequent symptom in people with Multiple Sclerosis. Whilst many respond to first line 
therapies it is estimated that 30 – 40% will have suboptimal treatment response requiring more 
specialised management. Such strategies include combination of oral medications, botulinum toxin, 
nabiximols and consideration of intrathecal therapies; baclofen or phenol. Early expert intervention 
as outlined in this review can have a positive impact on functional ability and quality of life for 
people with MS  
Multiple sclerosis (MS) is one of the leading causes of non-traumatic acquired disability in young 
people affecting more than 120,000 people in the UK and about 2.5 million people worldwide1. 
Significant advances have been made in MS disease modifying therapies (DMTs)  including the 
progressive phase 2. However, many people live with troublesome symptoms related to the disease. 
The North American Research Committee on MS (NARCOMS) Registry has identified 11 key symptom 
domains that are commonly affected in MS: mobility, hand function, tremor/coordination, vision, 
pain, fatigue, bowel/bladder function, sensory, spasticity, cognition, and depression 3. More than 80% 
of respondents reported spasticity during their disease course and spasticity severity was reported as 
moderate or high by between 35% and 54% of respondents. This was associated with stiffness, 
spasms, and/or pain, mainly in the lower limbs. Key aspects of managing MS-related spasticity are 
understanding the pathophysiology of spasticity, use of appropriate outcome measures and a 
personalised approach to pharmacological treatment in the context of the patient’s activities and 
quality of life. 
 Spasticity is defined by Lance as  “a motor disorder characterised by a velocity dependent increase in 
tonic stretch reflexes with exaggerated tendon jerks, resulting from hyperexcitability of the stretch 
reflex, as one component of the Upper Motor Neuron syndrome”. It is clinically important to 
differentiate between neural and non-neural components of stiffness to inform management. 
Optimum management requires a multidisciplinary team approach including a neurologist or 
rehabilitation medicine physician, physiotherapist, specialist nurse and access to occupational therapy 
and splinting.  
Assessment and outcome measures: 
Thorough assessment of the impact of spasticity on the individual is key. This involves accurate history 
taking as to the symptoms the individual experiences, diurnal variation, trigger factors including 
infections, bladder and bowel dysfunction, skin breakdown, suitability and fit of splints, and impact on 
walking and other activities. Generic and disease specific outcome measures can be used. A 
combination of objective (hands on) and patient reported outcome measures is essential to 
understand the degree of spasticity experienced and to monitor response to any intervention. The 
most commonly used measure is the Ashworth or modified Ashworth scales which are easy to 
administer in clinical practice4. There are conflicting reports. however, regarding the validity and 
reliability of these measures. The Tardieu scale, commonly used in cerebral palsy and stroke, has not 
been validated for use in MS spasticity 5. The MS spasticity scale (MSSS-88) is an 88 item patient-based 
interval level scale which evaluates the symptoms the patient experiences and how spasticity affects 
their daily life 6. The numerical rating scale for spasticity (NRS) is a 0 – 10 point scale where the 
individual will rate the severity of their spasticity over the previous 24 hours 7. There is concern, 
however, that the individual might rate other symptoms such as weakness or pain, rather than 
spasticity in isolation, however this may additionally reflect quality of life. Other measures which might 
be useful in clinical practice include a spasm score  or functional measures such as timed walking tests 
(25 foot walk, 10 metre walk) or measures of upper limb function (9 hole peg test). 
 Current pharmacological treatments: 
The basis of pharmacological treatment of MS spasticity remains with the use of first line agents: 
Baclofen, Tizanidine and Gabapentin (pregabalin)8. Whilst many will respond to such treatment about 
one third will continue to experience problematic symptoms9. Addition of second line agents such as 
benzodiazepines ( eg diazepam and clonazepam) may be helpful but are frequently associated with 
side effects including CNS depression, memory impairment are common as is dependence and 
withdrawal syndrome if stopped abruptly. Although there are distinct mechanism of actions,  many of 
these agents may serve to hypopolarise neurons, such as through opening of chloride channels 
(benzodiapezpines) or potassium channels and blockage of calcium channels (baclofen and 
cannabinoids), to block hyperexcitability, to quell the spastic response 10.  Dantrolene is unique in its 
mode of action impacting the contractile mechanism of skeletal muscle by decreasing the release of 
calcium. Its use is limited by frequent side effects including gastrointestinal symptoms, weakness, 
sedation and dizziness. The risk of hepatotoxicity is a major limiting factor and requires monitoring of 
liver function prior and during therapy. In a Cochrane review of anti-spasticity agents for MS the 
conclusions were that there was in general low quality evidence of the efficacy of these agents to treat 
MS related spasticity and that better outcome measures are required in trials to reflect efficacy and 
impact on quality of life 11. 
Cannabinoids and MS spasticity: 
Cannabis has been used recreationally and medicinally by people with MS for many years prompting 
a research programme investigating utility of cannabis-based medicinal products (CBMPs) in MS 12-14.  
Biologically there is evidence that cannabis-based products modulate spasticity via CB1 receptors 15. 
The whole plant extract contains hundreds of chemical entities, however the two components of 
greatest interest are delta9 tetrahydocannabinol (THC) and cannabidiol (CBD) as the major 
psyochactive and non-psychoactive ingredients of cannabis that has been recently approved for some 
epilepsy conditions, respectively. Studies investigating synthetic THC, whole plant extracts, smoked 
cannabis and  THC:CBD (Nabiximols) have been reported 12, 16-18.  In 2010 THC:CBD (Nabiximols) was 
licensed for moderate to severe MS related spasticity having shown a significant improvement in 
patient reported spasticity on the NRS as compared with placebo 18. In this pivotal trial the patient 
cohort was enriched only randomising responders to ongoing treatment or placebo. Use of an 
enriched design is controversial as is the NRS spasticity as the primary outcome, thus many regulatory 
bodies do not accept this as high quality evidence,  despite some positive evidence of effects on the 
Ashworth scale in small scale academic studies 19, 20. However, currently THC:CBD is unlicensed by the 
Food and Drug Administration (FDA) and variably reimbursed throughout Europe. In the UK, NICE MS 
clinical guideline have recommended against its use as it is not deemed cost-effective [NICE MS CG 
186 2014]. Cannabis based products are also available in North America, Australia and in some 
European countries and in November 2018 cannabis based products for medicinal use were moved to 
Schedule 2 of the Misuse of Drugs Regulations 2001 raising the profile and demand for CBMPs. Many 
people with MS are using CBD or whole plant products, however there is a lack of clinical trial evidence 
that these treatments are effective and there has yet to become a recognised supply route for medical 
practitioners 21.  
Botulinum toxin: 
BoNT mediates its effect by interfering intracellularly with the process of Ca2+ regulated synaptic 
vesicle exocytosis, and thereby preventing release of their contents into the synaptic cleft, namely 
acetylcholine 22. Early trials of BoNT in MS addressed hip adductor tone and showed a significant 
reduction in spasticity and an improvement in passive function, particularly perineal hygiene. It should 
be considered as a useful option for focal problems areas and avoids the central side effects of 
systemic agents.  A recent consensus group have published the UK National guidelines on use of 
botulinum toxin in the management of adult spasticity www.rcplondon.ac.uk/guidelines-
policy/spasticity-adults-management-using-botulinum-toxin 23. 
 Intrathecal Baclofen: 
Intrathecal baclofen (ITB) is administered via a programmable, subcutaneously implanted drug 
delivery system, delivering low doses of Baclofen directly intradurally around the spinal cord where 
GABA-B receptors are expressed in high density. It should be considered in people with predominantly 
lower limb spasticity inadequately managed by 1st and 2nd line oral agents. In our experience reporting 
the impact of ITB in 106 people with MS, the benefit of ITB has proved to be sustainable over time 
with a positive impact on the Ashworth scale, spasm scores and range of movement and has the added 
benefit of withdrawing oral medications and reduced side effects 24. Early series concentrated on 
people with significant levels of disability but more recently ITB proved to be effective in improving 
mobility in carefully selected individuals; prompting ITB to be considered earlier to improve or 
maintain walking 25 . The main concern in ambulatory individuals is that the therapeutic effect may 
increase weakness and negatively impact on walking and transfers as some people with MS are reliant 
on a degree of hypertonia to be able to transfer and mobilise. In our cohort at the NHNN we have 
found that  preserved baseline walking speed and lower limb muscle strength predict ambulation after 
ITB 25 {Sammaraiee, 2019 3287 /id}. Another recently published cohort following 47 subjects for up to 
1 year, 32 remained ambulatory for up to 1 year. Efficacy was also noted on modified Ashworth, NRS 
pain and spasm 26.   
Chemical Neurolysis: 
Chemical neurolysis consists of a either a local injection of ethanol  or phenol to manage an area of 
focal spasticity or when administered intrathecally for severe lower limb spasticity in people not 
appropriate for ITB.  As a focal treatment it may act as a substitute for BoNT if repeated injections are 
considered detrimental to the patient or not considered cost effective. This topic has previously been 
reviewed in ACNR 27{Gaid M, 2012 3291 /id}. Phenol or alcohol mediate their effect through two 
different pathways,  low dose eg 2% phenol for an  anaesthetic effect or high dose eg > 3% phenol for  
neurolysis causing denaturation and fibrosis of the nerve which is largely irreversible 28. Similarly low 
dose alcohol has an anaesthetic effect and high dose ( > 50%) is neurolytic. Following phenol 
treatment, partial nerve regeneration and sprouting occurs so that the clinical effect may ‘wear off ’ 
in about 30%.  In our experience intrathecal phenol is a highly effective treatment in carefully selected 
subjects. It will usually impair bowel bladder and sexual function and management plans must be in 
place in this regard.  At the NHNN over a 12 year period 2006 – 2018, 45 people underwent ITP 
successfully with a reduction in spasticity on the Ashworth scale, penn spasm scale and higher levels 
of comfort . Due to its destructive and potentially irreversible nature ITP remains a last resort. 
Treatment algorithm: 
  
Discussion: 
 Spasticity remains a problematic symptom in people with advanced MS and when sub-optimally 
treated leads to significant impairment and distress. Unlike the DMT options for MS there are limited 
new drugs for spasticity, nabiximols being the only recently licensed option, with severely restricted 
access. People with MS should be treated with at least 2 first line agents commencing at low doses 
and escalating the dose frequently until effect is gained, side effects appear or the maximum dose is 
reached. Second line agents should then be added for additional effect.  Botulinum toxin or focal nerve 
blocks are useful for localised problematic areas. In people, including those who remain ambulatory, 
who have failed 1st and 2nd line systemic agents, intrathecal therapies are reasonable options and they 
should be referred to specialised multidisciplinary service for optimal management.  
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